{"id":358462,"date":"2025-08-29T20:47:11","date_gmt":"2025-08-29T20:47:11","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-pharvaris-nv\/"},"modified":"2025-08-29T20:47:11","modified_gmt":"2025-08-29T20:47:11","slug":"how-to-buy-pharvaris-nv","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/","title":{"rendered":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-358462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m","h1_source":{"label":"H1","type":"text","formatted_value":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m"},"description":"Pharvaris N.V. (PHVS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Pharvaris N.V. (PHVS) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Nadir hastal\u0131k tedavisinde devrim yaratabilecek bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Pharvaris N.V. (PHVS), bilimsel at\u0131l\u0131mlar\u0131n finansal f\u0131rsatlarla bulu\u015ftu\u011fu heyecan verici biyoteknoloji yat\u0131r\u0131m d\u00fcnyas\u0131n\u0131 temsil ediyor. Bu \u0130svi\u00e7re-Hollanda \u015firketi, kal\u0131tsal anjiyo\u00f6dem i\u00e7in oral tedaviler geli\u015ftiriyor ve bu nadir hastal\u0131\u011f\u0131 y\u00f6netme \u015feklini potansiyel olarak d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor. Mevcut hisse performans\u0131ndan ak\u0131ll\u0131 giri\u015f stratejilerine kadar her \u015feyi ke\u015ffedece\u011fiz.","intro_source":{"label":"Intro","type":"text","formatted_value":"Nadir hastal\u0131k tedavisinde devrim yaratabilecek bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Pharvaris N.V. (PHVS), bilimsel at\u0131l\u0131mlar\u0131n finansal f\u0131rsatlarla bulu\u015ftu\u011fu heyecan verici biyoteknoloji yat\u0131r\u0131m d\u00fcnyas\u0131n\u0131 temsil ediyor. Bu \u0130svi\u00e7re-Hollanda \u015firketi, kal\u0131tsal anjiyo\u00f6dem i\u00e7in oral tedaviler geli\u015ftiriyor ve bu nadir hastal\u0131\u011f\u0131 y\u00f6netme \u015feklini potansiyel olarak d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor. Mevcut hisse performans\u0131ndan ak\u0131ll\u0131 giri\u015f stratejilerine kadar her \u015feyi ke\u015ffedece\u011fiz."},"body_html":"<h2>\ud83d\udcc8 Pharvaris Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>29 A\u011fustos 2025 itibar\u0131yla Pharvaris N.V. (PHVS), NASDAQ'ta <strong>22,84 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>4 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih\u2014Pharvaris'in bir sonraki kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu raporlar fiyatlar\u0131 dramatik \u015fekilde hareket ettirmi\u015ftir.<\/p> <p><strong>Kazan\u00e7 Raporlar\u0131 PHVS Hissesini Nas\u0131l Etkiler<\/strong><\/p> <table> <thead> <tr> <th>Tarih<\/th> <th>Olay<\/th> <th>Haber \u00d6ncesi Fiyat<\/th> <th>Haber Sonras\u0131 De\u011fi\u015fim<\/th> <\/tr> <\/thead> <tbody> <tr> <td>12 A\u011fu 2025<\/td> <td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td> <td>23,65 $<\/td> <td>Hafif tepki (<a href=\"https:\/\/www.chartmill.com\/news\/PHVS\/Chartmill-33023-Pharvaris-NV-NASDAQPHVS-Reports-Wider-Q2-2025-Loss-Highlights-Clinical-Trial-Progress\">Chartmill<\/a>)<\/td> <\/tr> <tr> <td>\u00d6nceki \u00c7eyrek<\/td> <td>Sermaye Art\u0131r\u0131m\u0131<\/td> <td>~20,00 $<\/td> <td>%15 art\u0131\u015f (<a href=\"https:\/\/www.nasdaq.com\/press-release\/pharvaris-reports-second-quarter-2025-financial-results-and-provides-business-update\">NASDAQ<\/a>)<\/td> <\/tr> <\/tbody> <\/table> <p><strong>Trend Analizi<\/strong>: Piyasa, 2. \u00c7eyrek 2025 kazan\u00e7lar\u0131na ra\u011fmen daha geni\u015f zararlar kar\u015f\u0131s\u0131nda hafif tepki g\u00f6sterdi; bu da yat\u0131r\u0131mc\u0131lar\u0131n k\u0131sa vadeli finansallardan ziyade uzun vadeli klinik sonu\u00e7lara odakland\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>Pharvaris hisseleri son alt\u0131 ayda etkileyici bir <strong>%48 kazan\u00e7<\/strong> sa\u011flad\u0131:<\/p> <ul> <li><strong>\u015eubat<\/strong>: 15,35-15,96 $ (tatil sonras\u0131 konsolidasyon)<\/li> <li><strong>Mart<\/strong>: 15,82-15,83 $ (istikrarl\u0131 birikim)<\/li> <li><strong>Nisan<\/strong>: 16,89-18,70 $ (diren\u00e7 seviyelerinin k\u0131r\u0131lmas\u0131)<\/li> <li><strong>May\u0131s<\/strong>: 16,97-16,99 $ (sa\u011fl\u0131kl\u0131 geri \u00e7ekilme)<\/li> <li><strong>A\u011fustos<\/strong>: 20-24 $ aral\u0131\u011f\u0131 (yaz rallisi)<\/li> <\/ul> <p><strong>Bu etkileyici y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p> <ul> <li>Temmuz 2025'te ba\u015far\u0131l\u0131 175 milyon $ sermaye art\u0131r\u0131m\u0131<\/li> <li>Faz 3 klinik denemelerde ilerleme<\/li> <li>35,60 $ ortalama fiyat hedefi ile g\u00fc\u00e7l\u00fc analist deste\u011fi<\/li> <\/ul>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 28-32 $ (4. \u00e7eyrek klinik verilerine ba\u011fl\u0131) \u2192 <strong>AL<\/strong><\/li> <li><strong>2026<\/strong>: 35-40 $ (potansiyel NDA ba\u015fvuru ba\u015far\u0131s\u0131)<\/li> <li><strong>2028<\/strong>: 45-55 $ (ticari lansman ivmesi)<\/li> <li><strong>2030<\/strong>: 60+ $ (pazar penetrasyonu ve geni\u015fleme)<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: <strong>Risk tolerans\u0131 y\u00fcksek uzun vadeli yat\u0131r\u0131mc\u0131lar<\/strong> i\u00e7in ideal. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 beklemeli.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/strong><\/p> <ul> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: Tek varl\u0131\u011fa ba\u011f\u0131ml\u0131l\u0131k, her \u015fey deucrictibant ba\u015far\u0131s\u0131na ba\u011fl\u0131<\/li> <li><strong>Nakit t\u00fcketimi<\/strong>: 2025 ilk yar\u0131da 91,82 milyon \u20ac zarar, devam eden finansman gerektirir<\/li> <li><strong>Reg\u00fclasyon gecikmeleri<\/strong>: FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemez olabilir<\/li> <li><strong>Y\u00fcksek volatilite<\/strong>: -2,81 beta de\u011feri a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131n\u0131 g\u00f6sterir<\/li> <\/ul> <p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p> <ul> <li><strong>200 milyon $ nakit pozisyonu<\/strong> 2027'ye kadar finansman sa\u011flar<\/li> <li><strong>Faz 3 verileri 4. \u00e7eyrek 2025'te bekleniyor<\/strong> - potansiyel b\u00fcy\u00fck kataliz\u00f6r<\/li> <li><strong>Enjeksiyon a\u011f\u0131rl\u0131kl\u0131 pazarda oral terapi avantaj\u0131<\/strong><\/li> <li><strong>Analist g\u00f6r\u00fc\u015f\u00fc<\/strong>: 5 al, 1 tut tavsiyesi ve 35,60 $ hedef fiyat<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a al\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong>: 4 Kas\u0131m kazan\u00e7 tarihini yak\u0131ndan takip edin<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong>: Dengeli bir portf\u00f6y i\u00e7in stabil temett\u00fc hisseleriyle destekleyin<\/li> <\/ol> <p>Mizahi bir yorum: \"PHVS ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici potansiyel, ancak deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde dramatik ruh hali de\u011fi\u015fimlerine haz\u0131rl\u0131kl\u0131 olun!\"<\/p>  <h2>\u2705 Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir i\u015flem platformu se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td> <td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>3<\/td> <td>\"PHVS\" aramas\u0131 yap\u0131n<\/td> <td>Do\u011fru sonu\u00e7lar i\u00e7in tam sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td> <td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>\u0130nceleyin ve onaylay\u0131n<\/td> <td>Emir detaylar\u0131n\u0131 son kez kontrol edin<\/td> <\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Pocket Option, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 yeni ba\u015flayanlar i\u00e7in eri\u015filebilir k\u0131lar:<\/p> <ul> <li><strong>Minimum depozito sadece 5 $<\/strong> - Stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li> <li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> - Herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Kripto, e-c\u00fczdan ve geleneksel se\u00e7eneklerle esneklik<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, yeni yat\u0131r\u0131mc\u0131lar\u0131n PHVS gibi karma\u015f\u0131k biyoteknoloji hisselerinde zorlanmadan gezinmesine yard\u0131mc\u0131 olur.<\/p>  <h2>\ud83c\udf0d Pharvaris 2025'te: Nadir Hastal\u0131kta Yenilik\u00e7i<\/h2> <p>Pharvaris, kal\u0131tsal anjiyo\u00f6dem i\u00e7in oral terapi geli\u015ftirmede \u00f6nc\u00fc konumdad\u0131r. \u015eirketin lider aday\u0131 deucrictibant, \u015fu anda enjeksiyonlara ba\u011f\u0131ml\u0131 binlerce hastan\u0131n tedavisini d\u00f6n\u00fc\u015ft\u00fcrebilir. Faz 3 verilerinin 4. \u00e7eyrek 2025'te ve potansiyel FDA ba\u015fvurusunun 2026'da beklenmesi, \u015firket i\u00e7in kritik bir d\u00f6nemi temsil ediyor.<\/p> <p><strong>2025 e\u011flenceli bilgi<\/strong>: Pharvaris, Temmuz ay\u0131nda 175 milyon $ tutar\u0131nda halka arz\u0131n\u0131 ba\u015far\u0131yla art\u0131rarak g\u00fc\u00e7l\u00fc kurumsal g\u00fcveni g\u00f6sterdi; teklif o kadar pop\u00fclerdi ki orijinal plandan art\u0131r\u0131ld\u0131!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Pharvaris Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>29 A\u011fustos 2025 itibar\u0131yla Pharvaris N.V. (PHVS), NASDAQ&#8217;ta <strong>22,84 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>4 Kas\u0131m 2025<\/strong> kesinlikle kritik bir tarih\u2014Pharvaris&#8217;in bir sonraki kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu raporlar fiyatlar\u0131 dramatik \u015fekilde hareket ettirmi\u015ftir.<\/p>\n<p><strong>Kazan\u00e7 Raporlar\u0131 PHVS Hissesini Nas\u0131l Etkiler<\/strong><\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>12 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>23,65 $<\/td>\n<td>Hafif tepki (<a href=\"https:\/\/www.chartmill.com\/news\/PHVS\/Chartmill-33023-Pharvaris-NV-NASDAQPHVS-Reports-Wider-Q2-2025-Loss-Highlights-Clinical-Trial-Progress\">Chartmill<\/a>)<\/td>\n<\/tr>\n<tr>\n<td>\u00d6nceki \u00c7eyrek<\/td>\n<td>Sermaye Art\u0131r\u0131m\u0131<\/td>\n<td>~20,00 $<\/td>\n<td>%15 art\u0131\u015f (<a href=\"https:\/\/www.nasdaq.com\/press-release\/pharvaris-reports-second-quarter-2025-financial-results-and-provides-business-update\">NASDAQ<\/a>)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Analizi<\/strong>: Piyasa, 2. \u00c7eyrek 2025 kazan\u00e7lar\u0131na ra\u011fmen daha geni\u015f zararlar kar\u015f\u0131s\u0131nda hafif tepki g\u00f6sterdi; bu da yat\u0131r\u0131mc\u0131lar\u0131n k\u0131sa vadeli finansallardan ziyade uzun vadeli klinik sonu\u00e7lara odakland\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>Pharvaris hisseleri son alt\u0131 ayda etkileyici bir <strong>%48 kazan\u00e7<\/strong> sa\u011flad\u0131:<\/p>\n<ul>\n<li><strong>\u015eubat<\/strong>: 15,35-15,96 $ (tatil sonras\u0131 konsolidasyon)<\/li>\n<li><strong>Mart<\/strong>: 15,82-15,83 $ (istikrarl\u0131 birikim)<\/li>\n<li><strong>Nisan<\/strong>: 16,89-18,70 $ (diren\u00e7 seviyelerinin k\u0131r\u0131lmas\u0131)<\/li>\n<li><strong>May\u0131s<\/strong>: 16,97-16,99 $ (sa\u011fl\u0131kl\u0131 geri \u00e7ekilme)<\/li>\n<li><strong>A\u011fustos<\/strong>: 20-24 $ aral\u0131\u011f\u0131 (yaz rallisi)<\/li>\n<\/ul>\n<p><strong>Bu etkileyici y\u00fckseli\u015fin nedeni nedir?<\/strong><\/p>\n<ul>\n<li>Temmuz 2025&#8217;te ba\u015far\u0131l\u0131 175 milyon $ sermaye art\u0131r\u0131m\u0131<\/li>\n<li>Faz 3 klinik denemelerde ilerleme<\/li>\n<li>35,60 $ ortalama fiyat hedefi ile g\u00fc\u00e7l\u00fc analist deste\u011fi<\/li>\n<\/ul>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 28-32 $ (4. \u00e7eyrek klinik verilerine ba\u011fl\u0131) \u2192 <strong>AL<\/strong><\/li>\n<li><strong>2026<\/strong>: 35-40 $ (potansiyel NDA ba\u015fvuru ba\u015far\u0131s\u0131)<\/li>\n<li><strong>2028<\/strong>: 45-55 $ (ticari lansman ivmesi)<\/li>\n<li><strong>2030<\/strong>: 60+ $ (pazar penetrasyonu ve geni\u015fleme)<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: <strong>Risk tolerans\u0131 y\u00fcksek uzun vadeli yat\u0131r\u0131mc\u0131lar<\/strong> i\u00e7in ideal. K\u0131sa vadeli yat\u0131r\u0131mc\u0131lar kazan\u00e7 sonras\u0131 f\u0131rsatlar\u0131 beklemeli.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<p><strong>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/strong><\/p>\n<ul>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: Tek varl\u0131\u011fa ba\u011f\u0131ml\u0131l\u0131k, her \u015fey deucrictibant ba\u015far\u0131s\u0131na ba\u011fl\u0131<\/li>\n<li><strong>Nakit t\u00fcketimi<\/strong>: 2025 ilk yar\u0131da 91,82 milyon \u20ac zarar, devam eden finansman gerektirir<\/li>\n<li><strong>Reg\u00fclasyon gecikmeleri<\/strong>: FDA onay s\u00fcreci \u00f6ng\u00f6r\u00fclemez olabilir<\/li>\n<li><strong>Y\u00fcksek volatilite<\/strong>: -2,81 beta de\u011feri a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131n\u0131 g\u00f6sterir<\/li>\n<\/ul>\n<p><strong>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/p>\n<ul>\n<li><strong>200 milyon $ nakit pozisyonu<\/strong> 2027&#8217;ye kadar finansman sa\u011flar<\/li>\n<li><strong>Faz 3 verileri 4. \u00e7eyrek 2025&#8217;te bekleniyor<\/strong> &#8211; potansiyel b\u00fcy\u00fck kataliz\u00f6r<\/li>\n<li><strong>Enjeksiyon a\u011f\u0131rl\u0131kl\u0131 pazarda oral terapi avantaj\u0131<\/strong><\/li>\n<li><strong>Analist g\u00f6r\u00fc\u015f\u00fc<\/strong>: 5 al, 1 tut tavsiyesi ve 35,60 $ hedef fiyat<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir Yat\u0131r\u0131mc\u0131 Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: T\u00fcm yat\u0131r\u0131m\u0131 tek seferde de\u011fil, par\u00e7a par\u00e7a al\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong>: 4 Kas\u0131m kazan\u00e7 tarihini yak\u0131ndan takip edin<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong>: Dengeli bir portf\u00f6y i\u00e7in stabil temett\u00fc hisseleriyle destekleyin<\/li>\n<\/ol>\n<p>Mizahi bir yorum: &#8220;PHVS ticareti, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014heyecan verici potansiyel, ancak deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde dramatik ruh hali de\u011fi\u015fimlerine haz\u0131rl\u0131kl\u0131 olun!&#8221;<\/p>\n<h2>\u2705 Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir i\u015flem platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 fonlay\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;PHVS&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 son kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Pocket Option, biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131 yeni ba\u015flayanlar i\u00e7in eri\u015filebilir k\u0131lar:<\/p>\n<ul>\n<li><strong>Minimum depozito sadece 5 $<\/strong> &#8211; Stratejileri d\u00fc\u015f\u00fck riskle test edin<\/li>\n<li><strong>1 dakikal\u0131k KYC s\u00fcreci<\/strong> &#8211; Herhangi bir kimlik belgesini y\u00fckleyin ve hemen i\u015flem yapmaya ba\u015flay\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Kripto, e-c\u00fczdan ve geleneksel se\u00e7eneklerle esneklik<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, yeni yat\u0131r\u0131mc\u0131lar\u0131n PHVS gibi karma\u015f\u0131k biyoteknoloji hisselerinde zorlanmadan gezinmesine yard\u0131mc\u0131 olur.<\/p>\n<h2>\ud83c\udf0d Pharvaris 2025&#8217;te: Nadir Hastal\u0131kta Yenilik\u00e7i<\/h2>\n<p>Pharvaris, kal\u0131tsal anjiyo\u00f6dem i\u00e7in oral terapi geli\u015ftirmede \u00f6nc\u00fc konumdad\u0131r. \u015eirketin lider aday\u0131 deucrictibant, \u015fu anda enjeksiyonlara ba\u011f\u0131ml\u0131 binlerce hastan\u0131n tedavisini d\u00f6n\u00fc\u015ft\u00fcrebilir. Faz 3 verilerinin 4. \u00e7eyrek 2025&#8217;te ve potansiyel FDA ba\u015fvurusunun 2026&#8217;da beklenmesi, \u015firket i\u00e7in kritik bir d\u00f6nemi temsil ediyor.<\/p>\n<p><strong>2025 e\u011flenceli bilgi<\/strong>: Pharvaris, Temmuz ay\u0131nda 175 milyon $ tutar\u0131nda halka arz\u0131n\u0131 ba\u015far\u0131yla art\u0131rarak g\u00fc\u00e7l\u00fc kurumsal g\u00fcveni g\u00f6sterdi; teklif o kadar pop\u00fclerdi ki orijinal plandan art\u0131r\u0131ld\u0131!<\/p>\n"},"faq":[{"question":"Pharvaris N.V. hisseleri nereden al\u0131nabilir?","answer":"Pharvaris N.V. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden \"PHVS\" sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Pharvaris hisseleri i\u00e7in riskler nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, y\u00fcksek nakit t\u00fcketimi, reg\u00fclasyon gecikmeleri ve y\u00fcksek fiyat volatilitesi bulunmaktad\u0131r."},{"question":"Pharvaris hisseleri i\u00e7in fiyat hedefleri nelerdir?","answer":"Analistlerin ortalama fiyat hedefi 35,60 $ civar\u0131ndad\u0131r. 2025 sonunda 28-32 $, 2030'da ise 60 $ ve \u00fczeri fiyatlar \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar Pharvaris hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyeti ortalamas\u0131 yaparak ve fiyat uyar\u0131lar\u0131 kurarak yat\u0131r\u0131m yapman\u0131z \u00f6nerilir. Ayr\u0131ca, riskleri dengelemek i\u00e7in portf\u00f6y\u00fcn\u00fcz\u00fc \u00e7e\u015fitlendirin."},{"question":"Pharvaris'in geli\u015ftirdi\u011fi tedavi nedir?","answer":"Pharvaris, kal\u0131tsal anjiyo\u00f6dem i\u00e7in oral tedavi geli\u015ftirmektedir. Lider aday\u0131 deucrictibant, enjeksiyonlara alternatif olarak hastalar\u0131n tedavisini kolayla\u015ft\u0131rmay\u0131 hedeflemektedir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Pharvaris N.V. hisseleri nereden al\u0131nabilir?","answer":"Pharvaris N.V. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online i\u015flem platformu \u00fczerinden \"PHVS\" sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Pharvaris hisseleri i\u00e7in riskler nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, y\u00fcksek nakit t\u00fcketimi, reg\u00fclasyon gecikmeleri ve y\u00fcksek fiyat volatilitesi bulunmaktad\u0131r."},{"question":"Pharvaris hisseleri i\u00e7in fiyat hedefleri nelerdir?","answer":"Analistlerin ortalama fiyat hedefi 35,60 $ civar\u0131ndad\u0131r. 2025 sonunda 28-32 $, 2030'da ise 60 $ ve \u00fczeri fiyatlar \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Yeni ba\u015flayanlar Pharvaris hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rarak, dolar maliyeti ortalamas\u0131 yaparak ve fiyat uyar\u0131lar\u0131 kurarak yat\u0131r\u0131m yapman\u0131z \u00f6nerilir. Ayr\u0131ca, riskleri dengelemek i\u00e7in portf\u00f6y\u00fcn\u00fcz\u00fc \u00e7e\u015fitlendirin."},{"question":"Pharvaris'in geli\u015ftirdi\u011fi tedavi nedir?","answer":"Pharvaris, kal\u0131tsal anjiyo\u00f6dem i\u00e7in oral tedavi geli\u015ftirmektedir. Lider aday\u0131 deucrictibant, enjeksiyonlara alternatif olarak hastalar\u0131n tedavisini kolayla\u015ft\u0131rmay\u0131 hedeflemektedir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T20:47:11+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m\",\"datePublished\":\"2025-08-29T20:47:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\",\"name\":\"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"datePublished\":\"2025-08-29T20:47:11+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/","og_locale":"tr_TR","og_type":"article","og_title":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T20:47:11+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m","datePublished":"2025-08-29T20:47:11+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/","name":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","datePublished":"2025-08-29T20:47:11+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals12.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-pharvaris-nv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Pharvaris N.V. (PHVS) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Pharvaris N.V. (PHVS) Hisse Senedine Yat\u0131r\u0131m"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":358464,"slug":"how-to-buy-pharvaris-nv","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Pharvaris N.V. (PHVS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Pharvaris N.V. (PHVS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-pharvaris-nv\/"},"pt_AA":{"locale":"pt_AA","id":358457,"slug":"how-to-buy-pharvaris-nv","post_title":"Como comprar a\u00e7\u00f5es da Pharvaris N.V. (PHVS) - Investimento em a\u00e7\u00f5es da Pharvaris N.V. (PHVS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-pharvaris-nv\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/358462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=358462"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/358462\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334090"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=358462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=358462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=358462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}